CoChat

Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets

Open access
DeVries, J. Hans, Bain, Stephen C., Rodbard, Helena W., Seufert, Jochen, D’Alessio, David, Thomsen, Anne B., Zychma, Marcin, Rosenstock, Julio, on behalf of the Liraglutide-Detemir Study Group · 2012 · Diabetes Care

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We evaluated the addition of liraglutide to metformin in type 2 diabetes followed by intensification with basal insulin (detemir) if glycated hemoglobin (A1C) ≥7%. RESEARCH DESIGN AND METHODS: In 988 participants from North America and Europe uncontrolled on metformin ± sulfonylurea, sulfonylurea was discontinued and liraglutide 1.8 mg/day added for 12 weeks (run-in). Subsequently, those with A1C ≥7% were randomized 1:1 to 26 weeks’ open-label addition of insulin detemir to metformin + liraglutide (n = 162) or continuation without insulin detemir (n = 161). Patients achieving A1C <7% continued unchanged treatment (observational arm). The primary end point was A1C change between randomized groups. RESULTS: Of 821 participants completing the run-in, 61% (n = 498) achieved A1C <7% (mean change −1.3% from 7.7% at start), whereas 39% (n = 323) did not (−0.6% from 8.3% at start). During run-in, 167 of 988 (17%) withdrew; 46% of these due to gastrointestinal adverse events. At week 26, A1C decreased further, by 0.5% (from 7.6% at randomization) with insulin detemir (n = 162) versus 0.02% increase without insulin detemir (n = 157) to 7.1 and 7.5%, respectively (estimated treatment difference −0.52 [95% CI −0.68 to −0.36]; P < 0.0001). Forty-three percent of participants with insulin detemir versus 17% without reached A1C <7%. Mean weight decreased by 3.5 kg during run-in, then by 0.16 kg with insulin detemir or 0.95 kg without insulin detemir. In the randomized phase, no major hypoglycemia occurred and minor hypoglycemia rates were 0.286 and 0.029 events per participant-year with and without insulin detemir (9.2 vs. 1.3%). CONCLUSIONS: Supplementation of metformin with liraglutide and then insulin detemir was well tolerated in the majority of patients, with good glycemic control, sustained weight loss, and very low hypoglycemia rates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1928

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial design (A) and trial flow diagram (B). *Two participants who had been randomized to the metformin and liraglutide control group received the wrong trial treatment. One participant was supplied with insulin detemir but withdrew before administering the treatment. The other participant should not have been randomized as her A1C level at week 0 was <7%. For the full analysis, these participants appear in the randomized control group, and for the safety analysis, they appear in their respective “treatment” groups (i.e., insulin detemir and observational groups, respectively).
Figure 1 Trial design (A) and trial flow diagram (B). *Two participants who had been randomized to the metformin and liraglutide control group received the wrong trial treatment. One participant was supplied with insulin detemir but withdrew before administering the treatment. The other participant should not have been randomized as her A1C level at week 0 was <7%. For the full analysis, these participants appear in the randomized control group, and for the safety analysis, they appear in their respective “treatment” groups (i.e., insulin detemir and observational groups, respectively).CC BY-NC-ND · PubMed Central
Figure 2 Glycemic efficacy, changes in body weight, and insulin detemir doses. Results from run-in to randomization (vertical dotted line) and from randomization to the end of the trial for change in A1C (A), change in body weight (B), and mean FPG (C). Data are means ± 2 SE from the full analysis set with no imputation. RT, randomized treatment group; RC, randomized control group; O, observational group. D: Self-monitored plasma glucose profiles before and after breakfast, lunch, and dinner and at bedtime for the treatment and control groups at weeks 0 and 26. ■, randomized treatment group; □, randomized control group; △, observational group. Dotted lines, 0 weeks; solid lines, 26 weeks. Vertical bars indicate ± 2 SEM. P values refer to differences between groups in the change from randomization (week 0) to week 26. E: Insulin detemir dose (prescribed dose, ○, left ordinate) and self-measured FPG (♦, right ordinate) during the 26-week randomized period for the insulin detemir treatment group. Dotted lines indicate 25th–75th percentiles.
Figure 2 Glycemic efficacy, changes in body weight, and insulin detemir doses. Results from run-in to randomization (vertical dotted line) and from randomization to the end of the trial for change in A1C (A), change in body weight (B), and mean FPG (C). Data are means ± 2 SE from the full analysis set with no imputation. RT, randomized treatment group; RC, randomized control group; O, observational group. D: Self-monitored plasma glucose profiles before and after breakfast, lunch, and dinner and at bedtime for the treatment and control groups at weeks 0 and 26. ■, randomized treatment group; □, randomized control group; △, observational group. Dotted lines, 0 weeks; solid lines, 26 weeks. Vertical bars indicate ± 2 SEM. P values refer to differences between groups in the change from randomization (week 0) to week 26. E: Insulin detemir dose (prescribed dose, ○, left ordinate) and self-measured FPG (♦, right ordinate) during the 26-week randomized period for the insulin detemir treatment group. Dotted lines indicate 25th–75th percentiles.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. Samarasinghe, 2008, The short term effects of exenatide therapy in insulin treated patients with type 2 diabetes mellitus–a new option to achieve weight loss (Abstract), Diabetologia, 51, S353

Cited by

See all 159

Metadata

Authors
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group
Affiliations
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Swansea University (GB)
  • Endocrine and Metabolic Associates, Rockville, Maryland
  • University Medical Center Freiburg (DE)
  • Cincinnati VA Medical Center (US)
  • Novo Nordisk (Denmark) (DK)
  • Medical City Dallas Hospital (US)
Corresponding author
Rosenstock, Julio
Venue
Diabetes Care
Published
2012-06-12
Volume
35
Issue
7
Pages
1446-1454
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2160274347
Cited by
159
References
27
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 3 · 2020: 5 · 2019: 5 · 2018: 9 · 2017: 6 · 2016: 18 · 2015: 25 · 2014: 27 · 2013: 33 · 2012: 13
FWCI
25.15
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lirias (KU Leuven) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by-nc-nd)
  • Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
Funders
  • American Diabetes Association
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • Amylin Pharmaceuticals
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Intarcia Therapeutics
  • MannKind Corporation
  • MacroGenics
  • Diabetes UK
  • Novo Nordisk
  • Servier
  • Daiichi Sankyo Europe
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, metformin, liraglutide, insulin detemir, weight loss, hypoglycemia, gastrointestinal adverse effects, GLP-1 receptor agonists, glycemic control
MeSH terms
Insulin Detemir, Liraglutide, Adolescent, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Insulin, Long-Acting, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. https://app.cochat.ai/papers/10.2337/dc11-1928
The paper
DeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group. (2012). Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Diabetes Care. https://doi.org/10.2337/dc11-1928

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.